Boston Scientific (NYSE:BSX) Price Target Raised to $84.00 at Robert W. Baird

Boston Scientific (NYSE:BSX) had its price objective upped by Robert W. Baird from $79.00 to $84.00 in a research report released on Thursday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $70.00 to $72.00 and gave the stock an overweight rating in a research note on Thursday, February 1st. JPMorgan Chase & Co. lifted their price target on shares of Boston Scientific from $60.00 to $72.00 and gave the stock an overweight rating in a research note on Thursday, February 1st. StockNews.com cut shares of Boston Scientific from a buy rating to a hold rating in a report on Saturday, March 16th. Evercore ISI increased their target price on shares of Boston Scientific from $68.00 to $72.00 and gave the company an outperform rating in a research report on Thursday, April 4th. Finally, Needham & Company LLC increased their target price on shares of Boston Scientific from $71.00 to $82.00 and gave the company a buy rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $74.27.

Boston Scientific Trading Up 0.5 %

NYSE BSX opened at $73.30 on Thursday. Boston Scientific has a one year low of $48.35 and a one year high of $74.39. The firm has a 50 day simple moving average of $67.68 and a 200-day simple moving average of $60.37. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The firm has a market cap of $107.54 billion, a price-to-earnings ratio of 61.60, a PEG ratio of 2.48 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the previous year, the firm earned $0.45 earnings per share. Equities research analysts anticipate that Boston Scientific will post 2.32 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the transaction, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,979 shares of company stock worth $3,418,529. 0.50% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

Institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. boosted its position in Boston Scientific by 5.6% during the third quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock worth $27,353,000 after purchasing an additional 27,620 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of Boston Scientific in the fourth quarter worth $5,116,000. Glenmede Trust Co. NA raised its holdings in shares of Boston Scientific by 12.1% in the third quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after acquiring an additional 1,123 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Boston Scientific by 2.1% in the third quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock worth $98,683,000 after acquiring an additional 38,249 shares during the last quarter. Finally, HealthInvest Partners AB acquired a new position in shares of Boston Scientific in the fourth quarter worth $3,746,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.